Companies/Coya Therapeutics, Inc.

Company profile

Coya Therapeutics, Inc.

NASDAQ: COYA · Healthcare · Biotechnology

PublicHQ Houston, TX · HarrisCIK 0001835022Reports USD

#655 of 1,418 Healthcare companies by revenuetop-quartile growth

EA Score

48D

FH 60DQ 33GM —SS 33

v0.1 · 55/100 weight · provisional

↑ Altman-Z, balance-sheet leverage · ↓ listing tenure, disclosure history

Methodology →

Revenue TTM

$8.0M

Rev growth YoY (TTM)

+1793.8%

Net income (FY)

-$21.2M

Employees

as of 2026-08-18

Market cap

$113.5M

as of 2026-08-18

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$7.9M$7.9M2025

Net income-$21.2M-$21.2M2025

Operating income-$22.6M-$22.6M2025

Total assets$50.0M$50.0M2025

Liabilities$6.9M$6.9M2025

Equity$43.0M$43.0M2025

Revenue trend

FY2023 – FY2025 · USD

FY23

$6.0M

FY23

$3.6M

FY24

$7.9M

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Coya Therapeutics, Inc.’s revenue?

Coya Therapeutics, Inc. booked $7.9M in FY2025 revenue, growing 124% year over year — faster than most Healthcare companies we track, at a -267.1% net margin.

Peers · Healthcare

Nuwellis, Inc.43D Solid Biosciences Inc.41D Nextleaf Solutions Ltd.57C Cogent Biosciences, Inc.48D Aclaris Therapeutics, Inc.47D Pulmatrix, Inc.46D

Neighbors

Harris →

Exxon Mobil Corporation$332.2B77B+Chevron Corporation$184.4B71B ConocoPhillips$51.8B76B+Quanta Services, Inc.$28.5B68B Waste Management, Inc.$25.2B82B+Phillips 66$132.4B73B

Key facts

CEOArun Swaminathan

SectorHealthcare

IndustryBiotechnology

HeadquartersHouston, TX

ExchangeNASDAQ: COYA

Employees8

IPO date2022-12-29

Latest filings

8-K2026-08-11 10-Q2026-08-11 8-K2026-06-25 DEF 14A2026-05-13 8-K2026-05-12 8-K2026-05-12 10-Q2026-05-12 8-K2026-04-02

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.